This research develops targeted radiopharmaceutical therapies for HER2-positive cancers. By attaching radioactive isotopes to trastuzumab, treatment delivers precise radiation to cancer cells, overcoming drug resistance. The work includes creating practical drug kits and aims to improve cancer outcomes by replacing non-specific therapies with highly accurate, targeted interventions.

This project develops an “Aptamer Express,” a DNA-based Trojan horse designed to bypass the brain’s protective barriers, target tumours, and deliver cancer-killing drugs directly to brain cancer cells. The approach aims to overcome treatment resistance, improve precision, and reduce side effects, offering new hope for patients and their families.